Elevated serum free light chains predict cardiovascular events in type 2 diabetes

Srikanth Bellary; Jeffrey M. Faint; Lakhvir K. Assi; Colin A. Hutchison; Stephen J. Harding; Neil T. Raymond; Anthony H. Barnett

doi:10.2337/dc13-2227

Elevated serum free light chains predict cardiovascular events in type 2 diabetes

Srikanth Bellary^*, Jeffrey M. Faint, Lakhvir K. Assi, Colin A. Hutchison, Stephen J. Harding, Neil T. Raymond, Anthony H. Barnett

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

Original language	English
Pages (from-to)	2028-2030
Number of pages	3
Journal	Diabetes Care
Volume	37
Issue number	7
Early online date	17 Apr 2014
DOIs	https://doi.org/10.2337/dc13-2227
Publication status	Published - 31 Jul 2014

Access to Document

10.2337/dc13-2227

Cite this

@article{dda49fb176a0449fbe3376eb9b06b025,

title = "Elevated serum free light chains predict cardiovascular events in type 2 diabetes",

abstract = "OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. {\textcopyright} 2014 by the American Diabetes Association.",

author = "Srikanth Bellary and Faint, {Jeffrey M.} and Assi, {Lakhvir K.} and Hutchison, {Colin A.} and Harding, {Stephen J.} and Raymond, {Neil T.} and Barnett, {Anthony H.}",

year = "2014",

month = jul,

day = "31",

doi = "10.2337/dc13-2227",

language = "English",

volume = "37",

pages = "2028--2030",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "7",

}

TY - JOUR

T1 - Elevated serum free light chains predict cardiovascular events in type 2 diabetes

AU - Bellary, Srikanth

AU - Faint, Jeffrey M.

AU - Assi, Lakhvir K.

AU - Hutchison, Colin A.

AU - Harding, Stephen J.

AU - Raymond, Neil T.

AU - Barnett, Anthony H.

PY - 2014/7/31

Y1 - 2014/7/31

N2 - OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

AB - OBJECTIVE: Elevated polyclonal serum immunoglobulin free light chains (FLCs; combined FLCκ+FLCλ [cFLC]) are associated with adverse clinical outcomes and increased mortality; we investigated cFLC and cardiovascular disease (CVD) events in type 2 diabetes. RESEARCH DESIGN AND METHODS: In a cohort study of 352 south Asian patients with type 2 diabetes, serum cFLC, high-sensitivity C-reactive protein (hsCRP), and standard biochemistry were measured. CVD events over 2 years were recorded and assessed usingmultiple logistic regression. RESULTS: cFLC levels were elevated significantly in 29 of 352 (8%) patients with CVD events during 2 years of follow-up (50.7 vs. 42.8mg/L; P = 0.004). Inmultivariate analysis, elevated cFLC (>57.2 mg/L) was associated with CVD outcomes (odds ratio 3.3 [95% CI 1.3-8.2]; P = 0.012) and remained significant after adjusting for age, albumin-to-creatinine ratio, diabetes duration, or treatment. CONCLUSIONS: cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation. © 2014 by the American Diabetes Association.

UR - http://www.scopus.com/inward/record.url?scp=84903526436&partnerID=8YFLogxK

U2 - 10.2337/dc13-2227

DO - 10.2337/dc13-2227

M3 - Article

C2 - 24742658

SN - 0149-5992

VL - 37

SP - 2028

EP - 2030

JO - Diabetes Care

JF - Diabetes Care

IS - 7

ER -

Elevated serum free light chains predict cardiovascular events in type 2 diabetes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this